Reverse transcriptase-polymerase chain reaction for prostate-specific antigen may be a prognostic indicator in breast cancer. by Lehrer, S. et al.
Britsh Journal of Cancer (1996) 74, 871-873
© 1996 Stockton Press All rights reserved 0007-0920/96 $12.00 $
Reverse transcriptase-polymerase chain reaction for prostate-specific
antigen may be a prognostic indicator in breast cancer
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Summary Among women with node-negative breast cancer and small tumours, it is important to identify
those with tumours that will recur, so that they may receive adjuvant therapy, while sparing those with
tumours that will not recur the hazards of adjuvant treatment. A reverse transcriptase-polymerase chain
reaction (RT-PCR) for prostate-specific antigen (PSA) may be used to identify circulating metastatic cells in
patients with prostate cancer. Approximately 30% of breast cancer cells also produce PSA. Therefore, we
tested the PSA RT-PCR assay on blood specimens from women with breast cancer. We evaluated 78 women at
Mount Sinai Medical Center with histologically confirmed breast cancer. Venous blood (5 cm3) from the
women was collected in ethylene diaminetetraacetic acid (EDTA)-treated collection tubes and approximately
400 ng of RNA from each sample was subjected to an RT-PCR. We were able to detect the amplified PSA
fragment in 18 of78 women with breast cancer; 7 of the 18 women with the PSA fragment had localised, small,
node-negative tumours, both oestrogen receptor (ER) positive and ER negative. We could not detect the
amplified PSA fragment in 20 normal women and 22 normal men. We conclude that PSA RT-PCR may be a
useful method for determining the presence of circulating metastatic cells in some women with node-negative
breast cancer, and therefore the potential for these women to develop recurrent disease and thus benefit from
adjuvant therapy.
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The need to identify breast cancer patients who will benefit
from adjuvant therapy, and to spare others the side-effects, is
spurring the evaluation of new prognostic indicators.
Adjuvant therapy prolongs the lives of many women with
breast cancer. But because it is difficult to determine which
patients' tumours will recur, many patients who do not need
treatment receive it nevertheless (Reynolds, 1994).
Thanks in part to earlier detection, nearly two-thirds of
newly diagnosed breast cancer cases have no lymph node
involvement. Of the 120 000 women every year in this
situation, 70-80% can be cured without adjuvant therapy.
How to locate the remaining 20-30% of node-negative
patients who should be given adjuvant therapy remains a
dilemma (Reynolds, 1994).
Tumour size, histological grading, node involvement,
lymphatic invasion (Leitner et al., 1995) and oestrogen
receptor (ER) status of the tumour are the most widely
accepted and widely used indicators employed to assess the
probability of tumour recurrence and the need for adjuvant
therapy. Other markers, such as tumour epidermal growth
factor receptor, tumour c-erbB-2 level, and tumour angiogen-
esis, are also used (Reynolds, 1994). However, many of these
markers are highly intercorrelated, so the information they
provide can be redundant (Reynolds, 1994).
A need exists to identify and develop independent
predictors of tumour recurrence. This task is impeded by
the complex biological interactions involved in breast cancer,
and the concomitant difficulty in predicting which potential
markers will provide the best prognostic information.
In a recent article, Katz et al. (1995) have shown that an
enhanced reverse transcriptase-polymerase chain reaction
(RT-PCR) for prostate-specific antigen (PSA) may be used
as an indicator of true pathological stage in patients with
prostate cancer. We wish to present our preliminary findings
suggesting that the same assay may also be.used to screen for
circulating metastatic cells in women with node-negative
breast cancer.
Circulating metastatic prostate cancer cells produce PSA.
The RT-PCR assay relies upon the fact that normally there
are no cells in the peripheral circulation expressing the PSA
gene. The assay uses the enzyme reverse transcriptase (RT) to
convert the PSA mRNA into DNA. The DNA is then
amplified by polymerase chain reaction (PCR), and the PSA
fragment detected by allele-specific oligonucleotide hybridisa-
tion (ASO). One metastatic prostate cancer cell in 100 000
white blood cells can be identified in this way (Katz et al.,
1994, 1995).
Approximately 30% of breast cancer cells produce PSA
(Monne et al., 1994; Yu et al., 1994, 1995; Diamandis et al.,
1994). Therefore, we tested the PSA RT-PCR assay on blood
specimens from women with breast cancer.
Patients and methods
We evaluated 78 women at Mount Sinai Medical Center with
histologically confirmed breast cancer. Patients were selected
if the extent of the disease was known and a peripheral blood
specimen was available. The mean age of the patients was
59+ 15 years (mean+s.d.). The youngest woman was 31 and
the oldest was 94.
RNA preparation
Venous blood (5 cm3) from the women was collected in
ethylene diaminetetraacetic acid (EDTA)-treated collection
tubes. The whole blood was subjected to a gradiant isolation
of nucleated cells using Ficoll (Accurate Chemical and
Scientific Corp, Westbury, NY, USA) (Moreno et al.,
1992). The mononuclear cell layer was aspirated, rediluted
in phosphate-buffered saline, and then centrifuged as
previously described (Moreno et al., 1992). After the
supernatant was discarded, the pellet was stored at -700C
or used directly for RNA extraction. After adding 2 ml of
RNAzol B (Biotecx Laboratories, Houston, TX, USA) and
0.2 ml of chloroform to the pellet, the preparation was mixed
vigorously and put on ice for 5 min. The suspension was then
centrifuged at 12 000 g (4°C) for 15 min. The aqueous phase
was transferred to a fresh tube and mixed with an equal
volume of isopropanol. The samples were then kept at
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by tumour cells in tissue and blood samples (Ghossein et al.,
1995). RT-PCR of keratin 19 (K19) transcripts has been used
to detect occult breast cancer in peripheral blood and bone
marrow (Datta et al., 1994). RT-PCR of MUCI mRNA,
which encodes a core protein of polymorphic epithelial
mucin, has been employed for the detection of micrometas-
tases in axillary lymph nodes of breast cancer patients
(Noguchi et al., 1994).
In this study, we used RT-PCR amplification of PSA
mRNA in peripheral blood of women with different stages of
breast cancer. PSA is a kallikrein-like protease that is
produced in prostatic epithelial cells and breast tumour
cells, as well as some ovarian, liver, kidney, adrenal, colon,
parotid and lung tumours (Diamandis and Yu, 1995).
Furthermore, recent evidence indicates that PSA is a
molecule produced by cells bearing steroid hormone
receptors under conditions of steroid hormone stimulation
(Diamandis and Yu, 1995).
The presence ofa PSA fragment that can be amplified was
an early event in many of our breast cancer cases (Figure 1).
Twenty-two per cent of cases that had been diagnosed less
than 12 months before were PSA positive. This finding
provides support for the theory that breast cancer is a
systemic disease from its inception (Fisher, 1980).
The proportion ofcases in which a PSA fragment could be
amplified (18 of 78) seems relatively high, given that Yu et al.
(1994) detected PSA in 30% of female and male breast
tumours. However, Yu et al. used immunoassay, which is
consistently less sensitive than the RT-PCR we employed.
As noted above, we could amplify the PSA fragment from
7 of 29 node-negative localised cases with small tumours,
both ER positive and ER negative. We conclude that PSA
RT-PCR may be a useful method for determining the
presence of circulating metastatic cells in some women with
node-negative breast cancer, and the potential for these
women to develop recurrent disease and thus benefit from
adjuvant therapy. Indeed, Katz et al. (1995) have shown that
circulating metastatic prostate cancer cells, detected by PSA
RT-PCR, are a risk factor for recurrent disease in men with
prostate cancer. We recommend that the role ofthe PSA RT-
PCR assay in breast cancer, as described in this article, be
investigated further.
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